The antioxidant tempol inhibits cardiac hypertrophy in the insulin-resistant GLUT4-deficient mouse in vivo

Journal of Molecular and Cellular Cardiology

Volumn 42, Issue 6, 2007, Pages 1119-1128

  Ritchie, R H ^a   Quinn, J M ^a,b   Cao, A H ^a   Drummond, G R ^c   Kaye, D M ^a   Favaloro, J M ^b   Proietto, J ^b   Delbridge, L M D ^b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Antioxidant; Collagen; Hypertrophy; Insulin resistance; NADPH oxidase

Indexed keywords

ANTIOXIDANT; BRAIN NATRIURETIC PEPTIDE; GLUCOSE TRANSPORTER 4; GLYCOGEN SYNTHASE KINASE 3BETA; MYOSIN HEAVY CHAIN BETA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TEMPOL; THIOREDOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; HEART VENTRICLE HYPERTROPHY; IN VIVO STUDY; INSULIN RESISTANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIOXIDANTS; CARDIOMEGALY; CYCLIC N-OXIDES; FEMALE; GLUCOSE TRANSPORTER TYPE 4; INSULIN RESISTANCE; MALE; MICE; MICE, KNOCKOUT; SPIN LABELS;

MUS;

EID: 34249710907     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2007.03.900     Document Type: Article

References (55)

1. Ostenson G.C. The pathophysiology of type 2 diabetes mellitus. Acta Physiol. Scand. 171 (2001) 241-247
2. Bella J.N., Devereux R.B., Roman M.J., Palmieri V., Liu J.E., Paranicas M., et al. Separate and joint effects of systemic hypertension and diabetes mellitus on left ventricular structure and function in American Indians. Am. J. Cardiol. 87 (2001) 1260-1265
3. Hayat S.A., Patel B., Khattar R.S., and Malik R.A. Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. Clin. Sci. 107 (2004) 539-557
4. Hsu K.L., Tsai C.H., Chiang F.T., Lo H.M., Tseng C.D., Wang S.M., et al. Myocardial mechanics and titin in experimental insulin-resistant rats. Jpn. Heart J. 38 (1997) 717-728
5. Dutta K., Podolin D.A., Davidson M.B., and Davidoff A.J. Cardiomyocyte dysfunction in sucrose-fed rats is associated with insulin resistance. Diabetes 50 (2001) 1186-1192
6. Iyer S.N., and Katovich M.J. Effect of acute and chronic losartan treatment on glucose tolerance and insulin sensitivity in fructose-fed rats. Am. J. Hypertens. 19 (1996) 662-668
7. Kamide K., Rakugi H., Higaki J., Okamura A., Nagai M., Moriguchi K., et al. The renin-angiotensin and adrenergic nervous system in cardiac hypertrophy in fructose-fed rats. Am. J. Hypertens. 15 (2002) 66-71
8. Kaczmarczyk S.J., Andrikopoulos S., Favaloro J., Domenighetti A.A., Dunn A., Ernst M., et al. Threshold effects of glucose transporter-4 (GLUT4) deficiency on cardiac glucose uptake and development of hypertrophy. J. Mol. Endocrinol. 31 (2003) 449-459
9. Cosenzi A., Bernobich E., Plazzotta N., Seculin P., Odoni G., and Bellini G. Lacidipine reduces high blood pressure and the target organ damage induced by high fructose diet in rats. J. Hypertens. 17 (1999) 965-971
10. Rosenkranz A.C., Hood S.G., Woods R.L., Dusting G.J., and Ritchie R.H. B-type natriuretic peptide prevents acute hypertrophic responses in the diabetic rat heart: importance of cyclic GMP. Diabetes 52 (2003) 2389-2395
11. Dhalla A.K., Hill M.F., and Singal P.K. Role of oxidative stress in transition of hypertrophy to heart failure. J. Am. Coll. Cardiol. 28 (1996) 506-514
12. Date M.O., Morita T., Yamashita N., Nishida K., Yamaguchi O., Higuchi Y., et al. The antioxidant N-2-mercaptopropionyl glycine attenuates left ventricular hypertrophy in in vivo murine pressure-overload model. J. Am. Coll. Cardiol. 39 (2002) 907-912
13. Ritchie R.H., and Delbridge L.M. Cardiac hypertrophy, substrate utilisation and metabolic remodelling - cause or effect?. Clin. Exp. Pharmacol. Physiol. 33 (2006) 171-178
14. Iglarz M., Touyz R.M., Viel E.C., Amiri F., and Schiffrin E.L. Involvement of oxidative stress in the profibrotic action of aldosterone. Interaction with the renin-angiotensin system. Am. J. Hypertens. 17 (2004) 597-603
15. Byrne J.A., Grieve D.J., Bendall J.K., Li J.M., Gove C., Lambeth J.D., et al. Contrasting roles of NADPH oxidase isoforms in pressure-overload versus angiotensin II-induced cardiac hypertrophy. Circ. Res. 93 (2003) 802-805
16. phox-containing NADH oxidase in lipopolysaccharide-induced tumor necrosis factor-alpha expression and myocardial depression. Circulation 111 (2005) 1637-1644
17. Cave A., Grieve D., Johar S., Zhang M., and Shah A.M. NADPH oxidase-derived reactive oxygen species in cardiac pathophysiology. Philos. Trans. R. Soc. Lond., B 360 (2005) 2327-2334
18. Sorescu D., and Griendling K.K. Reactive oxygen species, mitochondria, and NADPH oxidases in the development and progression of heart failure. Congest. Heart Fail. 8 (2002) 132-140
19. Sawyer D.B., Siwik D.A., Xiao L., Pimentel D.R., Singh K., and Colucci W.S. Role of oxidative stress in myocardial hypertrophy and failure. J. Mol. Cell Cardiol. 34 (2002) 379-388
20. Katakam P.V.G., Tulbert C.D., Snipes J.A., Erdos B., Miller A.W., and Busija D.W. Impaired insulin-induced vasodilation in small coronary arteries of Zucker obese rats is mediated by reactive oxygen species. Am. J. Physiol. 288 (2005) H854-H860
21. Guzik T.J., Mussa S., Gastaldi D., Sadowski J., Ratnatunga C., Pillai R., et al. Mechanisms of increased vascular superoxide production in human diabetes mellitus. Circulation 105 (2002) 1656-1662
22. Hink U., Li H., Mollnau H., Oelze M., Matheis E., Hartmann M., et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ. Res. 88 (2001) e14-e22
23. Doi K., Sawada F., Toda G., Yamachika S., Seto S., Urata Y., et al. Alteration of antioxidants during the progression of heart disease in streptozotocin-induced diabetic rats. Free Radic. Res. 34 (2001) 251-261
24. Thiemermann C., McDonald M.C., and Cuzzocrea S. The stable nitroxide, tempol, attenuates the effects of peroxynitrite and oxygen-derived free radicals. Crit. Care Med. 29 (2001) 223-224
25. 2α. Hypertension 33 (1999) 424-428
26. Laskowski A., Woodman O.L., Cao A.H., et al. Antioxidant actions contribute to the antihypertrophic effects of atrial natriuretic peptide in neonatal rat cardiomyocytes. Cardiovasc. Res. 72 (2006) 112-123
27. Goh S.S.C., Woodman O.L., Pepe S., Cao A.H., Qin C., and Ritchie R.H. The red wine antioxidant resveratrol prevents cardiomyocyte injury following ischemia-reperfusion via multiple sites and mechanisms. Antiox Redox Signal 9 (2007) 101-113
28. Zemel M.B., Peuler J.D., Sowers J.R., and Simpson L. Hypertension in insulin-resistant Zucker obese rats is independent of sympathetic neural support. Am. J. Physiol. 262 (1992) E368-E371
29. Stenbit A.E., Katz E.B., Chatham J.C., Geenen D.L., Factor S.M., Weiss R.G., et al. Preservation of glucose metabolism in hypertrophic GLUT4-null hearts. Am. J. Physiol. 279 (2000) H313-H318
30. Katz E.B., Stenbit A.E., Hatton K., DePinho R., and Charron M.J. Cardiac and adipose tissue abnormalities but not diabetes in mice deficient in GLUT-4. Nature 377 (1995) 151-155
31. Abel E.D., Kaulbach H.C., Tian R., Hopkins J.C., Duffy J., Doetschman T., et al. Cardiac hypertrophy with preserved contractile function after selective deletion of GLUT-4 from the heart. J. Clin. Invest. 104 (1999) 1703-1714
32. Zhang Y., Jang R., Mori T.A., et al. The anti-oxidant tempol reverses and partially prevents adrenocorticotropic hormone-induced hypertension in the rat. J. Hypertens. 21 (2003) 1513-1518
33. Ritchie R.H., Sun X.S., Bilszta J.L., Gulluyan L.M., and Dusting G.J. Cardioprotective actions of an N-terminal fragment of annexin-1 in rat myocardium in vitro. Eur. J. Pharmacol. 461 (2003) 171-179
34. Davidoff A.J., Davidson M.B., Carmody M.W., Davis M.E., and Ren J. Diabetic cardiomyocyte dysfunction and myocyte insulin resistance: Role of glucose-induced PKC activity. Mol. Cell. Biochem. 262 (2004) 155-163
35. 2-26 protects adult rat cardiac myocytes from cellular injury induced by simulated ischaemia. Br. J. Pharmacol. 145 (2005) 495-502
36. Dikalova A., Clempus R., Lassegue B., Cheng G., McCoy J., Dikalov S., et al. Nox1 overexpression potentiates angiotensin II-induced hypertension and vascular smooth muscle hypertrophy in transgenic mice. Circulation 112 (2005) 2668-2676
37. Kim Y.M., Guzik T.J., Zhang Y.H., Zhang M.H., Kattach H., Ratnatunga C., et al. A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation. Circ. Res. 97 (2005) 629-636
38. 2+ accumulation during reoxygenation of rat cardiomyocytes. Am. J. Physiol. 280 (2001) H344-H353
39. Hardt S.E., and Sadoshima J. Glycogen synthase kinase-3 beta: a novel regulator of cardiac hypertrophy and development. Circ. Res. 90 (2002) 1055-1063
40. Antos C.L., McKinsey T.A., Frey N., Kutschke W., McAnally J., Shelton J.M., et al. Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 907-912
41. Kraegen E.W., Sowden J.A., Halstead M.B., Clark P.W., Rodnick K.J., Chisholm D.J., et al. Glucose transporters and in vivo glucose uptake in skeletal and cardiac muscle: fasting, insulin stimulation and immunoisolation studies of GLUT1 and GLUT4. Biochem. J. 295 (1993) 287-293
42. Semeniuk L.M., Kryski A.J., and Severson D.L. Echocardiographic assessment of cardiac function in diabetic db/db and transgenic db/db-hGLUT4 mice. Am. J. Physiol. 283 (2002) H976-H982
43. Gibbs E.M., Stock J.L., McCoid S.C., Stukenbrok H.A., Pessin J.E., Stevenson R.W., et al. Glycemic improvement in diabetic db/db mice by overexpression of the human insulin-regulatable glucose transporter (GLUT-4). J. Clin. Invest. 95 (1995) 1512-1518
44. Garvey W.T., Hardin D., Juhaszova M., and Dominguez J.H. Effects of diabetes on myocardial glucose transport system in rats: implications for diabetic cardiomyopathy. Am. J. Physiol. 264 (1993) H837-H844
45. 1 receptor-G-protein coupling and function in obese Zucker rats. Diabetes 54 (2005) 2219-2226
46. Nassar T., Kadery B., Lotan C., Da'as N., Kleinman Y., and Haj-Yehia A. Effects of the superoxide dismutase-mimetic compound tempol on endothelial dysfunction in streptozotocin-induced diabetic rats. Eur. J. Pharmacol. 436 (2002) 111-118
47. Jagadeesha D.K., Lindley T.E., Deleon J., Sharma R.V., Miller F., and Bhalla R.C. Tempol therapy attenuates medial smooth muscle cell apoptosis and neointima formation after balloon catheter injury in carotid artery of diabetic rats. Am. J. Physiol. 289 (2005) H1047-H1053
48. phox homologues nox1 and nox4. Free Radical. Biol. Med. 39 (2005) 381-391
49. Ceriello A., Bortolotti N., Falleti E., Taboga C., Tonutti L., Crescentini A., et al. Total radical trapping antioxidant parameter in NIDDM patients. Diabetes Care 20 (1997) 194-197
50. Fortuno A., San Jose G., Moreno M.U., Beloqui O., Diez J., and Zalba G. Phagocytic NADPH oxidase overactivity underlies oxidative stress in metabolic syndrome. Diabetes 55 (2006) 209-215
51. Delbosc S., Paizanis E., Magous R., Araiz C., Dimo T., Cristol J.P., et al. Involvement of oxidative stress and NADPH oxidase activation in the development of cardiovascular complications in a model of insulin resistance, the fructose-fed rat. Atherosclerosis 179 (2005) 43-49
52. Al-Awwadi N.A., Araiz C., Bornet A., Delbosc S., Cristol J.P., Linck N., et al. Extracts enriched in different polyphenolic families normalize increased cardiac NADPH oxidase expression while having differential effects on insulin resistance, hypertension, and cardiac hypertrophy in high-fructose-fed rats. J. Agric. Food Chem. 53 (2005) 151-157
53. Ushio-Fukai M. Localizing NADPH oxidase-derived ROS. Sci. STKE 22 (2006)
54. Higashi M., Shimokawa H., Hattori T., Hiroki J., Mukai Y., Morikawa K., et al. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ. Res. 93 (2003) 767-775
55. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853